Market Research Report
Colorectal Cancer KOL Interview - US
|Published by||Datamonitor Healthcare||Product code||973503|
|Published||Content info||17 Pages
Delivery time: 1-2 business days
|Colorectal Cancer KOL Interview - US|
|Published: October 29, 2020||Content info: 17 Pages||
This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for colorectal cancer. Disease stratifications by staging and expression profile of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Keytruda, Braftovi, Opdivo, Avastin (and bevacizumab biosimilars), Herceptin (and trastuzumab biosimilars), Lonsurf, and Erbitux.